— Know what they know.
Not Investment Advice

NMRA NASDAQ

Neumora Therapeutics, Inc. Common Stock
1W: -26.2% 1M: -63.8% 3M: -70.4% YTD: -79.1% 1Y: -71.3%
$0.50
-0.05 (-9.11%)
 
Weekly Expected Move ±12.7%
$0 $0 $0 $1 $1
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 28 · $92.6M mcap · 62M float · 2.90% daily turnover · Short 48% of daily vol

Balance Sheet Trends

Total Assets
$191M -39.7% ▼
5Y CAGR: -0.7%
Total Liabilities
$87M +191.5% ▲
5Y CAGR: -21.5%
Shareholders Equity
$104M -63.8% ▼
Cash & Investments
$183M -40.7% ▼
5Y CAGR: -1.0%
Total Debt
$477K -74.3% ▼
5Y CAGR: -25.3%
Net Debt
-$182M -29.8% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$409M$241M$374M$142M$183M
Short-Term Investments$0$131M$80M$165M$0
Cash & ST Investments$409M$372M$454M$308M$183M
Net Receivables$200K$919K$939K$0$0
Inventory$0$0$0$0$0
Other Current Assets$125K$50K$0$6M$8M
Total Current Assets$416M$388M$478M$314M$191M
Property, Plant & Equip.$4M$11M$7M$3M$457K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$24M$10M$0$0
Other Non-Current Assets$10M$4M$1M$0$53K
Total Non-Current Assets$14M$38M$18M$3M$510K
Total Assets$429M$426M$496M$317M$191M
— Liabilities —
Accounts Payable$2M$7M$337K$3M$3M
Short-Term Debt$0$0$0$0$284K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$8M$10M$10M$10M$29M
Total Current Liabilities$23M$24M$25M$30M$32M
Long-Term Debt$0$0$0$0$193K
Other Non-Current Liab.$730M$844M$155K$22K$55M
Total Non-Current Liabilities$731M$849M$2M$22K$55M
Total Liabilities$755M$873M$27M$30M$87M
— Equity —
Common Stock$3K$3K$16K$16K$17K
Retained Earnings-$337M-$468M-$703M-$947M-$1.2B
Accumulated OCI$0-$774K-$76K$62K$0
Total Stockholders Equity-$325M-$447M$469M$287M$104M
Total Liabilities & Equity$429M$426M$496M$317M$191M
— Key Metrics —
Total Debt$2M$8M$5M$2M$477K
Net Debt-$407M-$233M-$369M-$140M-$182M
Total Investments$0$154M$90M$165M$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms